Dolutegravir for the treatment of HIV-2 infection

Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
Ana TreviñoVincent Soriano

Abstract

Therapeutic options are limited for HIV-2 infected persons, largely in part due to the lack of susceptibility to HIV-1 non-nucleoside reverse transcriptase inhibitors and poor susceptibility to some HIV-1 protease inhibitors. This is particularly worrisome for HIV-2 patients with prior antiretroviral failure. Report the virological response to dolutegravir in HIV-2-infected individuals. Retrospective observational assessment of all HIV-2 individuals treated with dolutegravir in Spain. From 297 HIV-2-infected individuals recorded at the Spanish national registry, 26% received antiretroviral therapy. Six out of 8 failing on raltegravir selected for integrase resistance mutations N155H (4), Y143G (1) and Q148R (1). Two patients bearing N155H subsequently received dolutegravir. Both experienced initially more than 1.5 log drop in plasma HIV-2 RNA and significant CD4 gains. Whereas one kept on undetectable viremia 6 months later, the other experienced viral rebound. Dolutegravir may be a good therapeutic option for patients with HIV-2 infection, including those that previously failed other integrase inhibitors.

References

Jul 25, 2009·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·María SalgadoBerta Rodés
Apr 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Antoine BenardUNKNOWN ACHIEV2E Collaboration Study Group
May 12, 2011·The Journal of Antimicrobial Chemotherapy·Ana TreviñoUNKNOWN HIV-2 Spanish Study Group
Aug 5, 2011·Journal of Clinical Microbiology·F DamondUNKNOWN ACHI(E)V(2E) Study Group
Feb 23, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Charlotte CharpentierMartin Obermeier
Apr 11, 2013·Antimicrobial Agents and Chemotherapy·Dana N RaugiUNKNOWN University of Washington-Dakar HIV-2 Study Group
Dec 19, 2013·Antiviral Research·Luis Menéndez-Arias, Mar Alvarez
Apr 24, 2014·Expert Opinion on Pharmacotherapy·Jose Vicente Fernandez-MonteroVicente Soriano

❮ Previous
Next ❯

Citations

Mar 27, 2015·Retrovirology·Robert A SmithUNKNOWN University of Washington-Dakar HIV-2 Study Group
Mar 31, 2017·AIDS·Carmen de MendozaUNKNOWN Spanish HIV-2 Network
Apr 20, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Selly BaUNKNOWN University of Washington–Dakar HIV-2 Study Group
Jul 18, 2018·Antimicrobial Agents and Chemotherapy·Robert A SmithUNKNOWN University of Washington-Dakar HIV-2 Study Group
Feb 13, 2019·The Journal of Antimicrobial Chemotherapy·S RequenaUNKNOWN HIV-2 Spanish Study Group
Feb 26, 2019·Antimicrobial Agents and Chemotherapy·Robert A SmithUNKNOWN University of Washington-Dakar HIV-2 Study Group
Apr 4, 2017·The Journal of Antimicrobial Chemotherapy·Silvia RequenaUNKNOWN Spanish HIV-2 Study Group
Aug 28, 2020·The New England Journal of Medicine·Geoffrey S GottliebRajesh T Gandhi
Jun 4, 2017·Retrovirology·Hannah J BarbianBeatrice H Hahn
Feb 6, 2020·AIDS Research and Therapy·S JespersenB L Hønge
Aug 17, 2020·Medicina clínica·Carmen de MendozaUNKNOWN en nombre del Grupo Español de Estudio del HTLV y VIH-2

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.